The 8 most recent market catalysts affecting $NAUT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 55
Roth Capital Partners Analyst Raises Nautilus Biotechnology Price Target
Roth Capital Partners analyst Max Masucci has raised the price target for Nautilus Biotechnology (NAUT) from $3.50 to $4.00, while reaffirming a bullish rating. This adjustment sig…
Oct 27, 2026
Corporate Catalyst
Bearish
Impact 75
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
Nautilus Biotechnology reported a net loss of $15.6 million for Q3 2026, an increase from $13.6 million in the prior year, primarily due to a 10% rise in operating expenses. While …
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 75
Nautilus Biotechnology shares are trading higher after Roth Capital initiated its coverage on the stock with a Buy rating and announced a price target of $3.5.
The initiation of coverage by a reputable investment bank like Roth Capital, coupled with a 'Buy' rating and a specific price target, acts as a significant positive catalyst for Na…
Sep 29, 2026
Corporate Catalyst
Neutral
Impact 65
Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5
Roth Capital analyst Max Masucci has initiated coverage on Nautilus Biotechnology (NAUT) with a 'Buy' rating and a price target of $3.5. This event is significant as new analyst co…
Sep 11, 2026
Corporate Catalyst
Neutral
Impact 65
Nautilus Biotechnology Files $300M Shelf Registration, Including $125M Nasdaq Common Stock ATM Offering Through TD Cowen
Nautilus Biotechnology filed an S-3 shelf registration statement, allowing them to offer and sell up to $300 million in various securities over time. Crucially, this includes a $12…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
Nautilus Biotechnology shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $4 price target.
The initiation of coverage by a reputable firm like Leerink Partners with an 'Outperform' rating is a significant positive catalyst for Nautilus Biotechnology. It signals to the ma…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
Leerink Partners Initiates Coverage On Nautilus Biotechnology with Outperform Rating, Announces Price Target of $4
Leerink Partners initiating coverage on Nautilus Biotechnology with an Outperform rating and a $4 price target is a positive development for the company. Analyst coverage can incre…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 55
Amazon Sold Holding In Nautilus Biotechnology
This headline indicates Amazon's decision to sell its holding in Nautilus Biotechnology. For Amazon, this is likely a minor portfolio adjustment with negligible impact on its overa…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.